Rheumatology & Autoimmune

4+ day, 6+ hour ago   (534+ words) Joint pain is common. It is so common that most people who develop it, particularly in mid-life and beyond, attribute it to wear and tear, overuse, or the general physical demands of getting older. In many cases, this attribution is…...

1+ day, 2+ hour ago   (182+ words) Biogen has announced 52-week results from the phase 2 part of the ongoing AMETHYST phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). The updated results, presented at the European Academy of Dermatology and Venereology (EADV) 2026 Congress…...

22+ hour, 38+ min ago   (52+ words) Lakefront Biotherapeutics has a meaningful opportunity with its asset gamgertamig for the treatment of rare autoimmune diseases, RBC Capital Markets said in a note Wednesday. Gamgertamig has... Biotechnology & Medical Research Lakefront Biotherapeutics' Gamgertamig Has Meaningful Opportunity in Rare Autoimmune Diseases,…...

9+ hour, 39+ min ago   (682+ words) A longitudinal fluoride PET/CT study shows that spinal lesions of axial spondyloarthritis shrink and cool down during biologic treatment while degenerative lesions remain unchanged, offering a new way to tell the two apart....

3+ day, 8+ hour ago   (217+ words) NAPERVILLE, Ill., Oct. 6, 2026 /PRNewswire/ -- For people with complex autoimmune and inflammatory diseases, getting answers can sometimes take years. Patients may move from one specialist to another, repeat tests and manage multiple medications while trying to piece together what is happening to…...

1+ day, 3+ hour ago   (82+ words) New research shows that the antiviral protein IFIT1 is elevated in immune cells of lupus patients, where it promotes cell death and inflammatory cytokine production, suggesting a role in disease progression. Subject of Research: The role of the interferon-stimulated gene IFIT1 in…...

1+ day, 18+ hour ago   (164+ words) – New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD – Longer-term flare protection and safety data from the INDIGO open-label extension will be presented on October 10 at the 6th International…...

2+ day, 5+ hour ago   (303+ words) Abstract: 2216Title: Obecabtagene autoleucel (obe-cel), a CD19-targeting Chimeric Antigen Receptor (CAR) T-cell Therapy, in Adults and Adolescents with Severe, Refractory Systemic Lupus Erythematosus (srSLE): Findings from the Phase I CARLYSLE StudySession date and time: Tuesday, November 10, 2026; 10:30 AM–12:30 PM ET Summary: Updated…...

1+ day, 20+ hour ago   (48+ words) Biogen said on Friday its experimental drug showed durable improvement in skin symptoms among patients with a type of autoimmune disease in a mid-stage study. Here are some details:... Biogen's experimental lupus drug shows benefit against skin symptoms Published on…...

1+ day, 21+ hour ago   (493+ words) Biogen Inc. announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study of litifilimab in people living with cutaneous lupus erythematosus. The updated results, presented......